NRx Pharmaceuticals (NASDAQ:NRXP) Earns Buy Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $34.00 target price on the stock.

A number of other equities analysts have also weighed in on the company. Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. BTIG Research restated a “buy” rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Four investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, NRx Pharmaceuticals has an average rating of “Hold” and an average target price of $36.75.

NRx Pharmaceuticals Trading Up 4.0%

NRXP opened at $1.80 on Tuesday. NRx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $3.84. The firm has a 50 day moving average of $2.21 and a two-hundred day moving average of $2.57. The firm has a market capitalization of $53.28 million, a PE ratio of -0.77 and a beta of 1.92.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $6.83 million. As a group, analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently bought and sold shares of NRXP. Anson Funds Management LP boosted its stake in shares of NRx Pharmaceuticals by 26.2% in the third quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock worth $6,683,000 after acquiring an additional 420,129 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after buying an additional 82,781 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $994,000. AdvisorShares Investments LLC lifted its stake in shares of NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after buying an additional 78,339 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in NRx Pharmaceuticals by 17.8% during the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after acquiring an additional 33,004 shares during the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.